A7i Intelligence Gulf Biotechnology Intelligence
Market

The infrastructure building the Gulf's biotechnology future

Track the laboratories, manufacturing facilities, research centres and clinical infrastructure expanding regional capability.

21 assets across the six markets

The green glass buildings of Cleveland Clinic Abu Dhabi among towers on Al Maryah Island
Cleveland Clinic Abu Dhabi on Al Maryah Island, an anchor partner of Hub71+ Life Sciences.Photo: Francisco Anzola, CC BY 3.0, cropped

Where the infrastructure is

Every life-science asset A7i has verified across the six Gulf states.

Data table
Every life-science asset in the A7i dataset
AssetLocationTypeStatusLatest updateSource
King Faisal Specialist Hospital and Research Centre, cell therapy programmeKing Faisal Specialist Hospital and Research CentreWith LiferaRiyadhSaudi ArabiaCell and gene therapy centreOperationalOctober 2025KFSHRC via GlobeNewswire
MS Pharma biologics facilityMS PharmaRiyadhSaudi ArabiaBiomanufacturing facilityOperationalAugust 2025BioPharma APAC
Lifera and National Resilience sterile injectables facilityLiferaWith National Resilience · Announced November 2023RiyadhSaudi ArabiaBiomanufacturing facilityUnder constructionTarget of more than 125 million units a yearNovember 2023Contract Pharma
SaudiBio insulin lineSaudiBio (Lifera)With Novo Nordisk Saudi Arabia · Announced October 2024 · Expected 2027 target for first GCC-produced innovator biologic insulinRiyadhSaudi ArabiaBiomanufacturing facilityUnder constructionTargeting more than 50% of Saudi insulin needsOctober 2024Lifera
Lifera Jeddah contract manufacturing siteLiferaAnnounced January 2026 · Expected Construction from early 2027, commissioning planned 2030JeddahSaudi ArabiaContract manufacturing facilityAnnouncedJanuary 2026BioProcess International
SFDA reference laboratorySaudi Food and Drug AuthorityEmerging signal, verification in progressDammamSaudi ArabiaReference laboratoryOperationalJune 2026Tracking
Saudi Biotechnology AcceleratorSaudi Biotechnology AcceleratorRiyadhSaudi ArabiaBiotechnology acceleratorOperational62 companies in the 2025 Biotechnology Venture Readiness Program cohortJanuary 2025Saudi Biotechnology Accelerator
King Abdullah University of Science and TechnologyKAUSTThuwalSaudi ArabiaResearch instituteOperationalSeptember 2023KAUST
Biosphere Labs, Masdar CityMasdar CityWith M42, Attentive ScienceAbu DhabiUAEShared laboratoryOperationalJune 2026Gulf News
Emirati Genome ProgrammeDepartment of Health Abu DhabiWith M42, G42Abu DhabiUAEGenomics programmeOperational780,000 UAE nationals took part, per the operator. Largest published analysis cohort is 43,608 individuals.September 2025M42
Abu Dhabi BiobankM42With BioTwinAbu DhabiUAEBiobankOperationalJune 2026Gulf News
Mubadala Bio DiabTec facilityMubadala BioWith BiosidusAbu DhabiUAEBiomanufacturing facilityOperationalMubadala Bio group: 10 facilities, 6 of them in the Emirates, producing 2.5bn tablets and capsules and 120m injectables a yearJune 2026Zawya
GEMMABio gene therapy centresDepartment of Health Abu Dhabi, M42 and PureHealthWith GEMMABio Therapeutics · Announced July 2025Abu DhabiUAECell and gene therapy centreProposedJuly 2025Department of Health - Abu Dhabi
MSD regional logistics hubMSDWith Department of Health Abu Dhabi · Announced June 2026Abu DhabiUAEDistribution infrastructureAnnouncedJune 2026World Pharma Today
Hub71+ Life SciencesHub71With Department of Health Abu Dhabi, Emirates Drug Establishment, HELM cluster, Cleveland Clinic Abu Dhabi · Announced October 2025Abu DhabiUAEBiotechnology acceleratorOperational12 partner organisationsOctober 2025Hub71
Julphar manufacturing complexGulf Pharmaceutical Industries (Julphar)Ras Al KhaimahUAEPharmaceutical plantOperationalAugust 2026Julphar
Qatar Precision Health InstituteQatar FoundationWith Qatar Research, Development and Innovation CouncilDohaQatarResearch instituteOperationalNearly 50,000 participants recruited across Qatar Biobank and Qatar Genome ProgrammeJanuary 2026Qatar Precision Health Institute
Sidra MedicineQatar FoundationDohaQatarClinical trial centreOperationalJuly 2026HealthCare MEA
Bahrain Oncology CentreGovernment of BahrainEmerging signal, verification in progressManamaBahrainClinical trial centreOperationalFebruary 2025Tracking
Al-Shifa pharmaceutical factoryKuwait-Saudi Pharmaceutical Industries CompanyEmerging signal, verification in progressKuwait CityKuwaitPharmaceutical plantOperationalMarch 2026Tracking
Oman pharmaceutical manufacturing build-outMultiple manufacturersEmerging signal, verification in progressA national build-out of 18 facilities, shown on the map as one country-level marker.MuscatOmanPharmaceutical plantUnder constructionReported as 18 facilities under construction alongside 20 operatingAugust 2026Khaleej Times
Sources: A7i facilities dataset, each asset individually sourced in the table below Methodology

Science-to-Export Value Chain

Nine stages from research to export, and what is verified at each.

STAGE 1 · OPERATING

Research

KAUST, King Faisal Specialist Hospital and Research Centre, Qatar Precision Health Institute, Sidra Medicine, Emirati Genome Programme, Biosphere Labs, Masdar City, Abu Dhabi Biobank, Qatar Biobank

  • A published analysis cohort of 43,608 individuals from the Emirati Genome Programme
  • About 50,000 participants recruited across the Qatari programmes
  • Commercially scaled shared laboratory capacity in Abu Dhabi

Next milestones

  • A consolidated count of peer-reviewed output from these programmes
STAGE 2 · DEVELOPING

Intellectual property

KAUST, Saudi Authority for Intellectual Property, WAYAKIT

  • University spinouts reaching commercial contracts

Next milestones

  • A first Gulf-originated biotechnology patent family with international grants
  • Published patent positions from companies in the tracker
  • Published licensing outcomes from university technology transfer offices
STAGE 3 · FORMING

Preclinical development

IMMUNORA, Valere Therapeutics, Nano Based, BioFiber Solutions, Revivo Rx, ONOIDS, Saudi Biotechnology Accelerator, Hub71+ Life Sciences

  • A 62-company accelerator cohort in Saudi Arabia, roughly a third of it domestically founded

Next milestones

  • Published preclinical data, funding rounds and development timelines
STAGE 4 · OPERATING

Clinical validation

King Faisal Specialist Hospital and Research Centre, IROS, Sidra Medicine, Halia Therapeutics

  • A Phase I approval for a CAR-T therapy developed in Saudi Arabia
  • A genomics-driven Alzheimer's prevention trial in Abu Dhabi
  • 48% of Saudi registered trials run by one institution in the first half of 2025

Next milestones

  • Trial capacity extending beyond the lead institutions
  • More trials of Gulf-originated assets, building on the Saudi CAR-T Phase I
STAGE 5 · STRONG

Regulatory approval

Saudi Food and Drug Authority, Emirates Drug Establishment

  • SFDA assessed at WHO Maturity Level 4 for medicines and vaccines
  • Frontier oncology and metabolic therapies cleared in the Gulf at or before Western markets
  • A single federal registration route in the UAE

Next milestones

  • WHO maturity recognition extended to medical devices
  • Published review timelines across all six states
  • A first approval of a Gulf-originated product
STAGE 6 · BUILDING

Manufacturing

Lifera, SaudiBio, MS Pharma, Mubadala Bio, Julphar, Arcera, Riyadh sterile injectables facility, DiabTec, Lifera Jeddah site

  • An operating SFDA-approved biologics plant
  • An operating biologics facility in Abu Dhabi producing under licence
  • Vaccine localisation memoranda with three tier-one manufacturers

Next milestones

  • Commissioning of the Riyadh sterile injectables facility, targeting more than 125 million units a year
  • Localisation agreements maturing into Gulf-owned process capability
  • Published output figures from the newer plants, following Mubadala Bio's group figures
STAGE 7 · OPERATING

Procurement and adoption

NUPCO, Department of Health Abu Dhabi, Dubai Health Authority, Ministry of Public Health Qatar

  • Advanced therapies reaching patients in Saudi Arabia, the UAE, Qatar and Bahrain

Next milestones

  • Published procurement volumes and award data
  • Evidence of localisation shaping procurement outcomes
STAGE 8 · BUILDING

Regional distribution

MSD, Aumet, Saudi Amarox, MSD Abu Dhabi logistics hub

  • A regional logistics hub announced in Abu Dhabi
  • Venture-funded distribution software scaling across the region
  • Commercialisation agreements with pre-negotiated GCC expansion

Next milestones

  • A centralised GCC route for devices and diagnostics, matching the pharmaceutical route
  • A published timeline for the Abu Dhabi logistics hub
STAGE 9 · DEVELOPING

Global export

PureHealth, WAYAKIT, Mubadala Bio, Arcera

  • Two closed outbound acquisitions into the United Kingdom, one of them in laboratory diagnostics
  • One Saudi-developed product with foreign commercial agreements

Next milestones

  • A first Gulf-originated therapy or diagnostic licensed out of the region
  • A first Gulf-developed product approved by a non-GCC regulator
  • A first Gulf asset entering a foreign clinical trial
  • Gulf-developed capability sold abroad, building on the outbound acquisitions to date
Data table
Value chain stage by stage, with verified achievements and next milestones
#Stage, and who is in itStatusVerified achievementsNext milestones
1ResearchKAUST, King Faisal Specialist Hospital and Research Centre, Qatar Precision Health Institute, Sidra Medicine, Emirati Genome Programme, Biosphere Labs, Masdar City, Abu Dhabi Biobank, Qatar BiobankOperating
  • A published analysis cohort of 43,608 individuals from the Emirati Genome Programme
  • About 50,000 participants recruited across the Qatari programmes
  • Commercially scaled shared laboratory capacity in Abu Dhabi
  • A consolidated count of peer-reviewed output from these programmes
2Intellectual propertyKAUST, Saudi Authority for Intellectual Property, WAYAKITDeveloping
  • University spinouts reaching commercial contracts
  • A first Gulf-originated biotechnology patent family with international grants
  • Published patent positions from companies in the tracker
  • Published licensing outcomes from university technology transfer offices
3Preclinical developmentIMMUNORA, Valere Therapeutics, Nano Based, BioFiber Solutions, Revivo Rx, ONOIDS, Saudi Biotechnology Accelerator, Hub71+ Life SciencesForming
  • A 62-company accelerator cohort in Saudi Arabia, roughly a third of it domestically founded
  • Published preclinical data, funding rounds and development timelines
4Clinical validationKing Faisal Specialist Hospital and Research Centre, IROS, Sidra Medicine, Halia TherapeuticsOperating
  • A Phase I approval for a CAR-T therapy developed in Saudi Arabia
  • A genomics-driven Alzheimer's prevention trial in Abu Dhabi
  • 48% of Saudi registered trials run by one institution in the first half of 2025
  • Trial capacity extending beyond the lead institutions
  • More trials of Gulf-originated assets, building on the Saudi CAR-T Phase I
5Regulatory approvalSaudi Food and Drug Authority, Emirates Drug EstablishmentStrong
  • SFDA assessed at WHO Maturity Level 4 for medicines and vaccines
  • Frontier oncology and metabolic therapies cleared in the Gulf at or before Western markets
  • A single federal registration route in the UAE
  • WHO maturity recognition extended to medical devices
  • Published review timelines across all six states
  • A first approval of a Gulf-originated product
6ManufacturingLifera, SaudiBio, MS Pharma, Mubadala Bio, Julphar, Arcera, Riyadh sterile injectables facility, DiabTec, Lifera Jeddah siteBuilding
  • An operating SFDA-approved biologics plant
  • An operating biologics facility in Abu Dhabi producing under licence
  • Vaccine localisation memoranda with three tier-one manufacturers
  • Commissioning of the Riyadh sterile injectables facility, targeting more than 125 million units a year
  • Localisation agreements maturing into Gulf-owned process capability
  • Published output figures from the newer plants, following Mubadala Bio's group figures
7Procurement and adoptionNUPCO, Department of Health Abu Dhabi, Dubai Health Authority, Ministry of Public Health QatarOperating
  • Advanced therapies reaching patients in Saudi Arabia, the UAE, Qatar and Bahrain
  • Published procurement volumes and award data
  • Evidence of localisation shaping procurement outcomes
8Regional distributionMSD, Aumet, Saudi Amarox, MSD Abu Dhabi logistics hubBuilding
  • A regional logistics hub announced in Abu Dhabi
  • Venture-funded distribution software scaling across the region
  • Commercialisation agreements with pre-negotiated GCC expansion
  • A centralised GCC route for devices and diagnostics, matching the pharmaceutical route
  • A published timeline for the Abu Dhabi logistics hub
9Global exportPureHealth, WAYAKIT, Mubadala Bio, ArceraDeveloping
  • Two closed outbound acquisitions into the United Kingdom, one of them in laboratory diagnostics
  • One Saudi-developed product with foreign commercial agreements
  • A first Gulf-originated therapy or diagnostic licensed out of the region
  • A first Gulf-developed product approved by a non-GCC regulator
  • A first Gulf asset entering a foreign clinical trial
  • Gulf-developed capability sold abroad, building on the outbound acquisitions to date
Sources: A7i facilities, capital, clinical, companies and exports datasets Methodology

Country-by-Sector Capability Index

A count of verified activity by market and sector, from A7i's own datasets.

Data table
A7i capability index: verified activity by market and sector
MarketCapitalBiomanufacturingPharmaceutical manufacturingGenomicsDiagnosticsClinical trialsCell and gene therapyAI drug discoveryLongevityAgricultural biotechnologyResearch infrastructureExport capability
Saudi Arabia332223312131
UAE322332111 33
Qatar1  3122   3 
Bahrain     11     
Kuwait  1         
Oman  2         

1 stated intent · 2 verified activity · 3 established activity. Hover a cell for the basis.

Sources: A7i capital, facilities, companies, clinical and exports datasets Methodology

The Wire, by email

Biotechnology, diagnostics, capital, regulation, science and manufacturing across the six Gulf markets. Every item is selected for its significance and carries a direct source and a verification date.